BlueSavant AI
BlueSavant AI is revolutionizing autism diagnosis with its BSAI DFx product, a groundbreaking diagnostic test utilizing a simple blood sample, gene expression analysis from RNA, and a proprietary machine learning model. This test can proactively identify autism in children as young as 18 months, even before symptoms appear, achieving 88% sensitivity. The technology aims to integrate into routine childcare, providing healthcare professionals with data-driven insights to enhance diagnostic capabilities and offer parents greater peace of mind. The company is working towards CAP CLIA accreditation for its US launch. By conducting more tests, BlueSavant AI aims to continuously improve its AI model's performance and contribute to a better understanding of ASD's genetic signatures.
BlueSavant AI
BlueSavant AI is revolutionizing autism diagnosis with its BSAI DFx product, a groundbreaking diagnostic test utilizing a simple blood sample, gene expression analysis from RNA, and a proprietary machine learning model. This test can proactively identify autism in children as young as 18 months, even before symptoms appear, achieving 88% sensitivity. The technology aims to integrate into routine childcare, providing healthcare professionals with data-driven insights to enhance diagnostic capabilities and offer parents greater peace of mind. The company is working towards CAP CLIA accreditation for its US launch. By conducting more tests, BlueSavant AI aims to continuously improve its AI model's performance and contribute to a better understanding of ASD's genetic signatures.